Tapering antidepressants: Is 3 months slow enough?

Medical Hypotheses

Volumn 77, Issue 6, 2011, Pages 1006-1008

  Phelps, James ^a  

^a Samaritan Mental Health and PsychEducationorg   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; OXYBATE SODIUM;

ARTICLE; CATAPLEXY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG WITHDRAWAL; HUMAN; NARCOLEPSY; REBOUND; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; NARCOLEPSY; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 80755140480     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.08.035     Document Type: Article

References (19)

1. Olfson M., Marcus C. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009, 66:848-856.
2. Schatzberg A.F., Blier P., Delgado P.O.L., et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006, 67(suppl 4):27-30.
3. Fava G.A., Bernardi M., Tomba E., et al. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007, 10:835-838.
4. Shelton R.C. Steps following attainment of remission: discontinuation of antidepressant therapy. Prim Care Companion J Clin Psychiatry 2001, 3:168-174.
5. Tint A., Haddad P.M., Anderson I.M. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 2008, 22:330-332.
6. Baldessarini R.J., Tondo L., Ghiani C., et al. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010, 167:934-941.
7. Dauvilliers Y., Arnulf I., Mignot E. Narcolepsy with cataplexy. Lancet 2007, 369:499-511.
8. Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatr Dis Treat 2008, 4:557-566.
9. Calabrò R.S., Savica R., Laganà A., et al. Status cataplecticus misdiagnosed as recurrent syncope. Neurol Sci 2007, 28:336-338.
10. Ristanovic R.K., Liang H., Hornfeldt C.S., et al. Exacerbation of cataplexy following gradual withdrawal of antidepressants: Manifestation of probable protracted rebound cataplexy. Sleep Med 2009, 10:416-421.
11. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415-21.
12. Harvey B.H., McEwen B.S., Stein D.J. Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression. Biol Psychiatry 2003, 54:1105-1117.
13. Riemann D., Berger M., Voderholzer U. Sleep and depression-results from psychobiological studies: an overview. Biol Psychol 2001, 57:67-103.
14. Ghaemi S.N., Ostacher M.M., El-Mallakh R.S., et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010, 71:372-380.
15. Faedda G.L., Tondo L., Baldessarini R.J., Suppes T., Tohen M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993, 50:448-455.
16. Baldessarini R.J., Tondo L., Faedda G.L., et al. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996, 57:441-448.
17. Associated Press. Stuck on meds: Some can't quit antidepressants. MSNBC, August 31, 2006 (available at, accessed 11.16.10). http://www.msnbc.msn.com/id/14126142/ns/health-mental_health.
18. Hunsberger J., Austin D.R., Henter I.D., et al. The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci 2009, 11:333-348.
19. Fava GA, Offidani E. The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2010 Aug 20. [Epub ahead of print].